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Pneumocystis jirovecii 
Pneumonia (PJP) is a very rare 
life-threatening pulmonary 
fungal infection that occurs 
in immunocompromised 
individuals including patients 
with inflammatory bowel 
disease (IBD). Prophylaxis for 
PJP is recommended in IBD 
patients treated with triple 
immunomodulators where one 
agent is a calcineurin inhibitor 
or an anti-TNFα1 but there is 
no consistency in a preventive 
approach in patients with double 
or single immunomodulators. 
Our aim was to describe the 
immunosuppressive treatment 
profile of IBD patients infected 
with PJP as well as the outcome 
of the disease. 
A total of 15 PJP infections were reported in 14 IBD patients 
(9 ulcerative colitis and 5 Crohn’s disease including 10 men and 
4 women). The median age at PJP diagnosis was 55 years (IQR 44-
80). Diagnosis was performed by a positive PJ polymerase chain 
reaction on the bronchoalveolar lavage in 87% of the cases and 
by a microscopic direct exam in 7% (unreported in 1 patient). 
One patient was co-infected by HIV and 57% were non-smokers. 
Immunosuppressive therapies at the time of diagnosis included 
steroids (n=11), thiopurines (n=9), infliximab (n=3), cyclosporin 
(n=2), methotrexate (n=1) and tacrolimus (n=1). Two PJP (13%) 
occurred in patients on triple immunosuppression, 9 patients (60 
%) had a double immunosuppressive treatment, 3 patients (20%) 
were on monotherapy and PJP in the HIV patient occurred in absence 
of immunosuppressive treatment (Table 1). None of the patients 
diagnosed with PJP had received prophylaxis. All patients were 
treated by trimethoprim/sulfamethoxazole or atovaquone and 5 
required an intensive care unit stay. Two patients (14%) died and 1 
patient had a recurrent episode 16 months after initial treatment. 
Evolution was favourable for the others.
Table 1: immunosuppressive treatment exposure in IBD patients at time of PJP 
(HIV patient excluded).
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This case series reports PJP in IBD patients while on single 
or double immunosuppression highlighting the risk in this 
population. Identifying risk factors for PJP infection in the IBD 
patients is essential to provide a case-by-case prophylaxis.





Steroid + thiopurine n=4
Steroid + infliximab n=1
Steroid + methotrexate n=1
Steroid + tacrolimus n=1
Infliximab + thiopurine n=2
Triple immunosuppression n=2
Steroid + thiopurine + cyclosporin n=2
Cases of PJP were retrospectively 
collected through the 
COllaborative Network For 
Exceptionally Rare case reports of 
the European Crohn’s and Colitis 
Organization (ECCO CONFER). All 
ECCO members were invited to 
report cases of PJP. Data were 
collected through a case report 
form. 
